Unitaid strategy 2013-2016
Key Performance Indicators 2013
Unitaid audited financial report for the year ended 31 December 2012
ACT Forecasting Report Q3-2012
Malaria diagnostics technology landscape – semi-annual update
Tuberculosis diagnostics technology & market landscape – semi-annual update
HIV/AIDS medicines and pipeline overview
Unitaid’s climate and health strategy 2023-2027
Unitaid’s investment case 2023-2027, executive summary
Unitaid’s investment case 2023-2027
Unitaid Strategy 2023-2027
Maternal and newborn health
Women’s and children’s health
Equitable access to therapeutics for pandemic preparedness and response
Overview of mpox antivirals and diagnostics landscape
Next generation pulse oximeters technology and market landscape
Malaria diagnostics market and technology landscape
Landscape of innovative tools and delivery strategies for eliminating vertical transmission of HIV, syphilis, hepatitis B, and chagas in endemic areas
Multipurpose prevention technologies: Technology landscape and potential for low- and middle-income countries
Screening and treatment for Chagas disease – technology and market landscape
Biomarkers for acute febrile illness at the point-of-care in low-resource settings. Technical working session. Meeting pre-reads
Unitaid and the Government of Spain
About Unitaid (Saving lives faster)
Unitaid and the UK Government
Unitaid audited financial report for the year ended 31 December 2023
Partnership report: Unitaid and the Global Fund to Fight AIDS, Tuberculosis and Malaria
Unitaid audited financial report for the year ended 31 December 2022
ACT Forecasting Report Q1-2012
Key Performance Indicators 2012
HIV, Tuberculosis and Malaria medicines landscape
Unitaid audited financial report for the period 2010-2011
Malaria diagnostics technology landscape
HIV/AIDS diagnostics technology landscape – semi-annual update
HIV simple/rapid, EIA, and supplemental test market analysis
